KADCYLA
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Recent trial shows greater invasive disease-free survival when treated with Kadcyla , (ado-trastuzumab emtansine)
1/4 Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast…
1/3 Roche’s Kadcyla reduced the risk of disease recurring in people with HER2positive early breast cancer with residual disease…
Approximately 25% of women who are diagnosed with breast cancer have HER2-positive tumors. The HER2 gene, which resides on…